Keryx Biopharmaceuticals  

(Public, NASDAQ:KERX)   Watch this stock  
Find more results for KERX
9.96
-0.34 (-3.25%)
After Hours: 10.05 +0.09 (0.90%)
May 6, 7:55PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 9.62 - 10.56
52 week 9.62 - 18.48
Open 10.35
Vol / Avg. 0.00/1.64M
Mkt cap 1.07B
P/E     -
Div/yield     -
EPS -1.22
Shares 103.60M
Beta 3.15
Inst. own 76%
Jun 16, 2015
Keryx Biopharmaceuticals Inc Annual Shareholders Meeting - 10:00AM EDT - Add to calendar
May 13, 2015
Keryx Biopharmaceuticals, Inc. at Bank of America Merrill Lynch 2015 Health Care Conference - 8:00PM EDT - Add to calendar
May 4, 2015
Q1 2015 Keryx Biopharmaceuticals Inc Earnings Release
May 4, 2015
Q1 2015 Keryx Biopharmaceuticals Inc Earnings Call - Webcast
Mar 9, 2015
Keryx Biopharmaceuticals Inc at ROTH Conference - Webcast
Mar 2, 2015
Keryx Biopharmaceuticals Inc at Cowen Health Care Conference - Webcast
Feb 27, 2015
Q4 2014 Keryx Biopharmaceuticals Inc Earnings Release
Feb 27, 2015
Q4 2014 Keryx Biopharmaceuticals Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -7079.97% -1030.19%
Operating margin -6966.08% -1027.52%
EBITD margin - -1024.69%
Return on average assets -140.18% -135.67%
Return on average equity -187.68% -187.61%
Employees 155 -
CDP Score - -

Address

750 Lexington Ave
NEW YORK, NY 10022-1200
United States - Map
+1-212-5315965 (Phone)
+1-212-5315961 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of renal disease. The Company is developing Zerenex (ferric citrate coordination complex), an oral, ferric iron-based compound. The Company has completed a United States-based Phase 3 clinical program for Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with chronic kidney disease, or CKD, on dialysis, conducted pursuant to a Special Protocol Assessment, or SPA, agreement with the United States Food and Drug Administration, or FDA. The Company has also completed a United States-based Phase 2 study of Zerenex for the management of elevated serum phosphorus levels and iron deficiency anemia in subjects with Stage 3 to 5 NDD-CKD.

Officers and directors

Michael P. Tarnok Independent Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
James F. Oliviero III Chief Financial Officer, Treasurer, Corporate Secretary
Age: 38
Bio & Compensation  - Reuters
Gregory P. Madison Chief Executive Officer, Director
Age: 46
Bio & Compensation  - Reuters
Brian R Adams Vice President, General Counsel
Bio & Compensation  - Reuters
Thomas M. Edwards Vice President - US Sales
Bio & Compensation  - Reuters
Abraham Ceesay Vice President of Marketing
Bio & Compensation  - Reuters
Daniel W. Olmstead Vice President - Payer Access
Bio & Compensation  - Reuters
Amit Sharma M.D. Vice President - Medical Affairs
Bio & Compensation  - Reuters
Amy B. Sullivan Vice President - Corporate Development and Public Affairs
Bio & Compensation  - Reuters
Douglass H. Laidlaw Ph.D. Director - Medical Affairs
Bio & Compensation  - Reuters